In the study published in the journal Science Signaling, the team led by LLuís Espinosa, investigator of IMIM's research group into stem cells and cancer, have shown that inhibition of
endosomal activity is a potential therapeutic strategy for the treatment of cancers with the BRAF mutated gene.